↓ Skip to main content

Dove Medical Press

Article Metrics

Protection of bone in premenopausal women with breast cancer: focus on zoledronic acid

Overview of attention for article published in International Journal of Women's Health, October 2012
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
7 Dimensions

Readers on

mendeley
16 Mendeley
Title
Protection of bone in premenopausal women with breast cancer: focus on zoledronic acid
Published in
International Journal of Women's Health, October 2012
DOI 10.2147/ijwh.s29101
Pubmed ID
Authors

Rebecca Aft

Abstract

Maintaining bone health is important for patients with breast cancer (BC), the most commonly diagnosed cancer in American women. Indeed, bone loss is common throughout the BC disease continuum. In the metastatic BC setting, patients are likely to develop bone metastases, a painful complication that can lead to potentially debilitating skeletal-related events. Bone health is equally important for patients with early BC. During adjuvant therapy for early BC, the largest challenge to bone health is from accelerated bone mineral density (BMD) loss. Although decreased BMD is well recognized in older, postmenopausal women, it may be underestimated in younger, premenopausal women undergoing endocrine therapy for BC. The rate and extent of cancer therapy-induced bone loss (from chemotherapy or endocrine therapy) are substantially greater than normal decreases in BMD during menopause. Bisphosphonates such as zoledronic acid (ZOL) are antiresorptive agents indicated for the treatment of bone metastases from BC. Clinical trials over the past few years suggest that, although not yet approved for this indication, ZOL can prevent cancer therapy-induced bone loss and improve BMD in premenopausal women receiving adjuvant (endocrine or chemo-) therapy for BC. Furthermore, the benefits of ZOL therapy may go beyond maintaining bone health and include potential anticancer benefits together with favorable tolerability and cost/benefit profiles. This review will focus specifically on the role of ZOL in preserving the bone health of premenopausal women with BC.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 16 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 16 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 4 25%
Other 3 19%
Student > Doctoral Student 2 13%
Student > Ph. D. Student 2 13%
Unspecified 1 6%
Other 1 6%
Unknown 3 19%
Readers by discipline Count As %
Medicine and Dentistry 12 75%
Unspecified 1 6%
Social Sciences 1 6%
Agricultural and Biological Sciences 1 6%
Unknown 1 6%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 October 2012.
All research outputs
#13,168,099
of 16,569,218 outputs
Outputs from International Journal of Women's Health
#466
of 594 outputs
Outputs of similar age
#111,016
of 152,310 outputs
Outputs of similar age from International Journal of Women's Health
#10
of 13 outputs
Altmetric has tracked 16,569,218 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 594 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.4. This one is in the 12th percentile – i.e., 12% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 152,310 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 13th percentile – i.e., 13% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one is in the 15th percentile – i.e., 15% of its contemporaries scored the same or lower than it.